E
NTLA icon

Ergoteles’s Intellia Therapeutics NTLA Stock Holding History

Ergoteles’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-15,473
Closed -$801K – 1843
2022
Q2 		$801K Buy
15,473
+2,703
+21% +$137K 0.02% 642
2022
Q1 		$928K Buy
+12,770
New +$1.08M 0.04% 453

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ergoteles's NTLA Position: Q3 2022 in Review

Ergoteles sold out of Intellia Therapeutics (NTLA) in Q3 2022, closing a stake of 15,473 shares — an estimated $801K sold.

Ergoteles first reported a position in NTLA in Q1 2022 and held it in 2 quarters. The position peaked at $928K in Q1 2022. 319 funds tracked by Wall St. Rank hold NTLA as of Q3 2022.

  • Ergoteles reported no remaining Intellia Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Ergoteles sold 15,473 Intellia Therapeutics shares in Q3 2022, an estimated $801K.
  • Ergoteles first reported a position in Intellia Therapeutics in Q1 2022 and held it in 2 quarters.
  • Ergoteles's Intellia Therapeutics position peaked at $928K in Q1 2022.
  • 319 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.